At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Pazopanib Hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pazopanib Hydrochloride for Von Hippel-Lindau Syndrome. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVon Hippel-Lindau Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartJan 2012
Primary CompletionMar 2024
TodayJul 2026
First PostedSep 19, 2011
Enrollment StartJan 17, 2012
Primary CompletionMar 13, 2024
TodayJul 1, 2026
Enrollment to primary: 12.2 yearsPosted 14.8 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pazopanib Hydrochloridedrug
Given PO